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coagulation disorder due to cholestasis. With the rh-IGF1 injection treatment, the patient's vitamin K and ursodeoxycholic acid, his cholestasis and his liver dysfunction were improved (AST 97 IU/L , ALT 35 IU/L, T-bil 0.4 mg/dL) at 1 year old. At 2 years old, the patient's serum glucose level after meals and HbA1C value (Japan Diabetes Society) had worsened (> 600 mg/dL and 8.6 %-9.4%, respectively) despite the increased bolus of rh-IGF1 [0.03 mg/kg] after meals and the continuous subcutaneous infusion of rh-IGF1 [0.6 mg/kg/day]. Accordingly, the both bolus of rh-IGF-1 and a subcutaneous injection of a rapid-acting insulin analog (8 IU) after meals, in addition to the continuous subcutaneous infusion of rh-IGF1 [0.6 mg/ kg/day] and α-glycosidase inhibitor, were initiated from the patient's age of 2 years onward. His HbA1C value remains high (9.7 % at 2 years + 1 month of age), and hypoglycemia in the fasting state continues. In addition, the patient suffered from pneumonia and asthmatic bronchitis several times and, developed an upper airway obstruction due to adenoidal hypertrophy. Oxygen administration and biphasic positive airway pressure treatment were initiated from 2 years onward. After the patient underwent a tonsillectomy at 2 years and 6 months old, his respiratory problems improved. from 38 mg/dL in the fasting state to over 200 mg/dL at the postprandial state. The fasting plasma insulin level was significantly above average at 6702 mU/mL. The results of all other laboratory tests were within normal range. From these findings, the patient was clinically diagnosed with leprechaunism, and we subsequently analyzed the patient's INSR gene.
At 24 days old, his weight gain was extremely poor and we began rhIGF1 treatment: rh-IGF1was subcutaneously injected, at a low concentration, twice a day and was gradually increased up to four times per day, and finally injected continuously at the dose of 1.0 mg /kg /day. Although the patient's serum insulin/glucose ratio and body weight improved, his weight was not normalized ( Fig. 2) . At 172 days old, we began a continuous rh-IGF1 subcutaneous infusion. At 1 month old, the patient exhibited pale stool, macrohematuria, extremely low levels of hepaplastin test (5%), hyperbilirubinemia (direct bilirubin: 1.6 mg/dL), and liver dysfunction (Aspartate transaminase: AST,100-235 IU/L and alanine aminotransferase: ALT, 15-80 IU/L). At 5 months old, scintigraphy tests revealed delayed biliary excretion, and a liver biopsy at 6 months old showed mild hepatitis, partial fibrosis, and accumulation of glycogen in the hepatocytes (Fig.1B ). From these findings, the patient was diagnosed with cholestasis and . The preparation of cell lysates, immunoprecipitation, and immunoblotting were performed as described [7] . We conducted each experiment at least three times, and the mean relative intensity of tyrosine phosphorylation from three different experiments was obtained ( Fig. 4B ).
Statistical analysis
Statistical analysis was performed using the Excel software and Student's t-test. The results are shown as mean ± SE. P < 0.05 was considered statistically significant.
Results

Missense mutation (T910M or E1047K) of the INSR gene
In the patient, we identified a heterozygous C to T substitution at position 2919 (NM_000208.2, c. 2919 C>T) that resulted in a threonine (ACG) to methionine (ATG) substitution at residue 910 (mature peptide numbering), and a heterozygous G to A mutation at position 3269 and 3271 (NM_000208.2, c.3269G>A, C.3271G to A) that resulted in a glutamine (GAG)
Materials and Methods
Sequence analysis of the INSR gene
Genomic DNA was isolated from peripheral blood lymphocytes of the patient and his parents, and amplified by PCR as described [7, 8] .
Plasmid construction
Flag tagged-pCMV-human INSR cDNA was provided by Dr. Masanori Iwaki (The University of Osaka, Osaka, Japan). A mutated INSR expression vector (p. T910M) was constructed by a 2919 C to T (NM_000208.2, c. 2919 C>T) point mutation using primers (5′T C T T G G A T G G A A3′, where T is the mutation site), and a mutated INSR expression vector (p. E1047K) was constructed by a 3269 G to A and 3271G to A (NM_000208.2, c.3269G>A, C.3271G to A) point mutation using the primer (5′A A T A A A G C C T C3′, where A is the mutation site). All mutations were confirmed by DNA sequencing and performed by Life Technologies Japan (Tokyo, Japan).
Immunoblotting analysis
COS-7 cells (0.5 -1.0 × 10 6 ) were transiently transfected with either the WT, T910M, or E1047K INSR construct with Lipofectamine 2000 (Invitrogen,Carlsbad, CA), according to the manufacturer's protocol, and to lysine (AAA) substitution at residue 1047 (mature peptide numbering) in the INSR β subunit (Fig.3) . Although the INSR T910M mutation has been reported in patients with leprechaunism [9] , this is the first report of an INSR E1047K mutation in a patient with leprechaunism. The E1047 mutation was not detected in our patient's parents, but a heterozygous T910M mutation was detected in his mother (Fig.3) . Accordingly, the E1047 mutation is considered a de novo mutation. Since the patient's case presents the characteristic clinical findings of leprechaunism, his case is considered to be a compound heterozygous INSR gene mutation (p.T910M and p. E1047K).
T910M and E1047K gene mutations diminish the insulin-dependent phosphorylation of INSR
To understand the functions of these mutations, we studied the insulin-dependent autophosphorylation of the INSR β subunit. In cells expressing E1047K, insulin-dependent autophosphorylation of E1047K INSR did not occur (10 ng/mL, 0.00 ± 0.01 vs. 0.86 ± 0.16, p< 0.05; 100ng/mL,; 0.01± 0.01 vs. 0.97 ± 0.01, p < 0.05), and the autophosphorylation of T910M INSR was significantly decreased compared to WT (10 ng/mL, 0.24 ± 0.05 vs. 0.86 ± 0.16, p < 0.05; 100 ng/mL, 0.22± 0.01 vs. 0.97 ± 0.05, p < 0.05) (Fig 4) . Moreover, cells expressing T910M INSR had lower INSR levels compared to WT and E1047K-expressing cells, despite higher levels of the proreceptor, consistent with a previous report that T910M results in the failure to process the INSR prore- started rapid insulin treatment and α-glycosidase inhibitor. In addition, our patient is suffering from upper airway obstruction due to adenoidal hypertrophy, which might be related to a side effect of rh-IGF1 treatment. This sequence of events explains why IGF1 is not able to compensate for INSR. Severe fasting hypoglycemia, as our patient also showed, is one of the characteristics of leprechaunism. This suggests an accelerated fasting state with rapid depletion of hepatic glycogen [13, 14] . In contrast, other studies have found that patients with leprechaunism do not exhibit glycogen depletion, and they propose that, since insulin has a low affinity to IGF1R, the high insulin levels in humans may cause hypoglycemia by binding to IGF1R [15] . Consistent with this, the hepatic histological finding in our patient also revealed an accumulation of glycogen in hepatocytes. Notably, in our patient, hypoglycemia might have been induced by high insulin levels that result in IGF1R binding.
In conclusion, we report a surviving case of leprechaunism, bearing a novel heterozygous compound missense mutation (p.T910M and p. E1047K), who is being treated with rh-IGF1. The rhIGF1 treatment is thought to have contributed to the patient's survival, but it did not prevent diabetes. We suggest that to improve the condition of patient with complete INSR dysfunction, another treatment along with rhIGF1 may be effective.
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ceptor [9] . In light of these findings, it appears that these compound heterozygous mutations lead to dysfunctional insulin signaling that results in leprechaunism.
Discussion
We have described the case of a surviving patient with leprechaunism (Donohue syndrome) bearing novel compound heterozygous mutations in the INSR gene (p.T910M and p.E1047K), who is being treated with rh-IGF1.
We newly identified an INSR E1047K mutation in our patient, and we found that the mutation led to absence of insulin-dependent INSR autophosphorylation. Since the Glu 1047 insulin receptor has been reported to be an important residue for ATP binding and, as such, the phosphorylation of INSR [10, 11] , our findings follow this line. However, the INSR T910M mutation has been reported in patients with leprechaunism [9] , and has been reported that T910M INSR leads to a failure of processing the proreceptor, as is consistent with our data. Accordingly, these findings suggest that the patient's INSR function is nearly absent.
It is well known that the insulin and IGF receptors are structurally related and share common post-receptor signaling pathways. The rh-IGF1 treatment for leprechaunism exploits these commonalities, thus rescuing the failed INSR signaling found in leprechaunism [5, 12] and resulting in prolonged patient survival [5] . With the present patient, we also started rh-IGF1treatment early, with a resulting survival over 2 years. However, the rhIGF-1 treatment was not able to prevent the development of diabetes in the patient, therefore we
